Long Jiaye, Cui Kai, Wang Du, Qin Shuxin, Li Zhong
Department of Interventional Radiology, Inner Mongolia Forestry General Hospital, The Second Clinical Medical School of Inner Mongolia University for the Nationalities, Tongliao, China.
Department of Medical Imaging, Inner Mongolia Forestry General Hospital, The Second Clinical Medical School of Inner Mongolia University for the Nationalities, Tongliao, China.
Cancer Control. 2024 Jan-Dec;31:10732748241310573. doi: 10.1177/10732748241310573.
The incidence and mortality of hepatocellular carcinoma (HCC) and its underlying etiologies in China are still unclear. Therefore, this study used the Global Burden of Disease (GBD) 2021 to evaluate the incidence and mortality of HCC and its underlying etiologies in China.
We extracted the incident cases, incidence rate, deaths, and mortality rate of HCC and its underlying etiologies in China in 1990 and 2021 from the GBD database. In addition, we used joinpoint regression analysis to assess the trend of the incidence rate and mortality rate of HCC and its underlying etiologies in China from 1990 to 2021.
The incidence of HCC in China climbed from 96,434.35 in 1990 to 196,636.59 in 2021, while the number of deaths rose from 94,937.12 in 1990 to 172,068.40 in 2021. From 1990 to 2021, the age-standardized incidence rate (ASIR) and age-standardized mortality rate (ASMR) of HCC in China decreased by 0.31 (95% CI: 0.23, 0.39) and 0.79 (95% CI: 0.28, 1.30), respectively. ASIR demonstrated a decreasing trend in HCC caused by different etiologies, such as HCC due to hepatitis B (HCCDHB), HCC due to hepatitis C (HCCDHC), and HCC due to other causes (HCCDOC), but an increasing trend in HCC due to alcohol use (HCCDAU) and HCC due to NASH (HCCDNASH). Between 1990 and 2021, ASMR showed a downward trend in HCCDHB, HCCDHC, and HCCDOC, while the trend in HCCDAU and HCCDNASH was not significant.
In the past 30 years, although the overall incidence rate and mortality of HCC in China have declined, the proportion of HCCDAU and HCCDNASH has increased due to the increasingly serious problems of alcoholism and obesity. Therefore, interventions are needed to address the issues of alcohol consumption and obesity in order to control the incidence of HCCDAU and HCCDNASH.
中国肝细胞癌（HCC）的发病率、死亡率及其潜在病因仍不明确。因此，本研究利用《2021年全球疾病负担》（GBD 2021）评估中国HCC的发病率、死亡率及其潜在病因。
我们从GBD数据库中提取了1990年和2021年中国HCC及其潜在病因的发病例数、发病率、死亡数和死亡率。此外，我们使用Joinpoint回归分析评估了1990年至2021年中国HCC及其潜在病因的发病率和死亡率趋势。
中国HCC的发病率从1990年的96434.35例攀升至2021年的196636.59例，而死亡人数从1990年的94937.12例增至2021年的172068.40例。1990年至2021年，中国HCC的年龄标准化发病率（ASIR）和年龄标准化死亡率（ASMR）分别下降了0.31（95%CI：0.23，0.39）和0.79（95%CI：0.28，1.30）。ASIR在由不同病因引起的HCC中呈下降趋势，如乙型肝炎所致HCC（HCCDHB）、丙型肝炎所致HCC（HCCDHC）和其他原因所致HCC（HCCDOC），但在酒精所致HCC（HCCDAU）和非酒精性脂肪性肝炎所致HCC（HCCDNASH）中呈上升趋势。1990年至2021年期间，HCCDHB、HCCDHC和HCCDOC的ASMR呈下降趋势，而HCCDAU和HCCDNASH的趋势不显著。
在过去30年中，尽管中国HCC的总体发病率和死亡率有所下降，但由于酗酒和肥胖问题日益严重，HCCDAU和HCCDNASH的比例有所增加。因此，需要采取干预措施来解决饮酒和肥胖问题，以控制HCCDAU和HCCDNASH的发病率。
